PMID- 37799329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231026
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 34
DP  - 2023 Dec 12
TI  - The decoy oligodeoxynucleotide against HIF-1alpha and STAT5 ameliorates atopic 
      dermatitis-like mouse model.
PG  - 102036
LID - 10.1016/j.omtn.2023.102036 [doi]
LID - 102036
AB  - Atopic dermatitis (AD) is a common inflammatory skin disease caused by an immune 
      disorder. Mast cells are known to be activated and granulated to maintain an 
      allergic reaction, including rhinitis, asthma, and AD. Although hypoxia-inducible 
      factor-1 alpha (HIF-1alpha) and signal transducer and activator of transcription 5 
      (STAT5) play crucial roles in mast cell survival and granulation, their effects 
      need to be clarified in allergic disorders. Thus, we designed decoy 
      oligodeoxynucleotide (ODN) synthetic DNA, without open ends, containing 
      complementary sequences for HIF-1alpha and STAT5 to suppress the transcriptional 
      activities of HIF-1alpha and STAT5. In this study, we demonstrated the effects of 
      HIF-1alpha/STAT5 ODN using AD-like in vivo and in vitro models. The HIF-1alpha/STAT5 
      decoy ODN significantly alleviated cutaneous symptoms similar to AD, including 
      morphology changes, immune cell infiltration, skin barrier dysfunction, and 
      inflammatory response. In the AD model, it also inhibited mast cell infiltration 
      and degranulation in skin tissue. These results suggest that the HIF-1alpha/STAT5 
      decoy ODN ameliorates the AD-like disorder and immunoglobulin E (IgE)-induced 
      mast cell activation by disrupting HIF-1alpha/STAT5 signaling pathways. Taken 
      together, these findings suggest the possibility of HIF-1alpha/STAT5 as therapeutic 
      targets and their decoy ODN as a potential therapeutic tool for AD.
CI  - (c) 2023 The Authors.
FAU - Gwon, Mi-Gyeong
AU  - Gwon MG
AD  - Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
FAU - Leem, Jaechan
AU  - Leem J
AD  - Department of Immunology, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
FAU - An, Hyun-Jin
AU  - An HJ
AD  - Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
FAU - Gu, Hyemin
AU  - Gu H
AD  - Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
FAU - Bae, Seongjae
AU  - Bae S
AD  - Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
FAU - Kim, Jong Hyun
AU  - Kim JH
AD  - Department of Biochemistry, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
FAU - Park, Kwan-Kyu
AU  - Park KK
AD  - Department of Pathology, School of Medicine, Daegu Catholic University, Daegu 
      42472, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20230920
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC10550406
OTO - NOTNLM
OT  - HIF-1alpha
OT  - MT: Oligonucleotides: Therapies and Applications
OT  - STAT5
OT  - atopic dermatitis
OT  - decoy oligodeoxynucleotide
OT  - mast cell
COIS- The authors declare no competing interests.
EDAT- 2023/10/06 06:43
MHDA- 2023/10/06 06:44
PMCR- 2023/09/20
CRDT- 2023/10/06 03:48
PHST- 2023/04/02 00:00 [received]
PHST- 2023/09/15 00:00 [accepted]
PHST- 2023/10/06 06:44 [medline]
PHST- 2023/10/06 06:43 [pubmed]
PHST- 2023/10/06 03:48 [entrez]
PHST- 2023/09/20 00:00 [pmc-release]
AID - S2162-2531(23)00254-8 [pii]
AID - 102036 [pii]
AID - 10.1016/j.omtn.2023.102036 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2023 Sep 20;34:102036. doi: 10.1016/j.omtn.2023.102036. 
      eCollection 2023 Dec 12.